Cargando…
ADAM8 is expressed widely in breast cancer and predicts poor outcome in hormone receptor positive, HER-2 negative patients
BACKGROUND: Breast malignancies are the predominant cancer-related cause of death in women. New methods of diagnosis, prognosis and treatment are necessary. Previously, we identified the breast cancer cell surface protein ADAM8 as a marker of poor survival, and a driver of Triple-Negative Breast Can...
Autores principales: | Pianetti, Stefania, Miller, Kathy D., Chen, Hannah H., Althouse, Sandra, Cao, Sha, Michael, Steven J., Sonenshein, Gail E., Mineva, Nora D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422820/ https://www.ncbi.nlm.nih.gov/pubmed/37568162 http://dx.doi.org/10.1186/s12935-023-03024-3 |
Ejemplares similares
-
miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells
por: Das, Sonia G., et al.
Publicado: (2016) -
ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis
por: Romagnoli, Mathilde, et al.
Publicado: (2014) -
Epigallocatechin-3-Gallate Inhibits Stem-Like Inflammatory Breast Cancer Cells
por: Mineva, Nora D., et al.
Publicado: (2013) -
Elevated serum HER‐2 predicts poor prognosis in breast cancer and is correlated to ADAM10 expression
por: Zheng, Hui, et al.
Publicado: (2019) -
HER2 somatic mutations are associated with poor survival in HER2‐negative breast cancers
por: Wang, Tonghui, et al.
Publicado: (2017)